| Development
Terminated |
| GW420867X/HBY1293 |
GlaxoSmithKline |
JAIDS
2000; also summer IAS meeting
|
| ALX40-4C |
Allelix Pharmaceuticals |
Formulation difficulties, lack of efficacy
|
| AMD3100 |
AnorMed
Inc. |
Cardiac arrhythmias
at high doses, lack of efficacy at low |
| PD-178390 |
Parke-Davis |
Casualty
of Pfizer merger |
| CI-1012 |
Parke-Davis |
Casualty
of Pfizer merger |
| PNU-142721 |
Pharmacia & Upjohn |
Casualty of P&U’s decision to leave HIV field |
| NSC 651016 |
Pharmacia & Upjohn |
Casualty of P&U’s decision to leave HIV field |
| UC781 |
Biosyn Inc. |
Being developed as topical microbicide
|
|
zintevir/AR-177 |
Antigenics
(formerly Aronex) |
Terminated subsequent to takeover and poor results |
| Clinical Hold |
|
emtricitabine/FTC/Coviracil |
Triangle/Abbott
|
Submission of NDA to be significantly delayed
|
|
(-)dOTC/BCH-10618/SPD754 |
Shire
Pharmaceuticals PLC |
Deaths in monkeys |
|
capravirine/S-1153/AG-1549 |
Agouron (Pfizer) |
Vasculitis
in dogs may mean curtains for cap. |
| mozenavir/DMP-450 |
DuPont
(now BMS) |
Electro-cardiographic
abnormalities in animals |
| Glacial Development |
|
Pentafuside/T-20
|
Trimeris/Roche
|
48-week results released; NDA to be filed 2nd half 2002 |
| T-1249 |
Trimeris/Roche
|
Phase I; longer half-life may allow QD dosing |
| Late Pipeline |
|
emivirine/MKC-442/Coactinon |
Triangle/Abbott
|
Triangle hopes to file NDA by year end; ICAAC
|
| Middle Pipeline |
| atazanavir/BMS-232632 |
Bristol-Myers
Squibb |
Moving slowly but
deliberately through phase II
|
| tipranavir |
Boehringer-Ingelheim |
"Trinity of major obstacles,” paper at summer IAS
|
|
VX-175/GW433908 |
Vertex/GlaxoSmithKline
|
Amprenavir
prodrug, PK dose-ranging at 8CROI
|
| SCH-C |
Schering/Praecis
|
Results of 8-week study presented at 9CROI |
| PRO 542 |
Progenics Pharmaceuticals |
Phase II, being
studied in combination with T-20
|
| DPC-083 |
DuPont (now BMS) |
Eyed
to hit market in 2003; paper at 7CROI
|
| TMC-125 |
Tibotec/Virco |
"Amazing potency" unveiled at 9CROI; to file NDA 2004 |
| Deep Pipeline |
| dADP/amdoxovir |
Triangle
Pharmaceuticals |
Phase
I/II dose ranging study presented at 8CROI
|
| TMC-120 |
Tibotec/Virco |
Paper at 8CROI
|
| TMC-126 |
Tibotec/Virco |
Paper at 8CROI
|
| DPC-961,
DPC-963 |
DuPont (BMS) |
Atazanavir may take priority over these |
| Calanolide-A |
SarawakMed |
Paper on this at 7CROI
|
| GPG-NH2 |
Tripep
AB/Karolinska Institute |
Early activity
in humans not too impressive |
| SCH-D |
Schering/Praecis
|
Follow-up compound to SCH-C |
| UK-427,857 |
Pfizer |
Said
to be moving into Phase I "soon” |
| DPC-681,
DPC-684 |
DuPont (BMS) |
Phase I studies on-going; paper
at 8CROI
|
| AMD-3465, 8445, 8664
|
AnorMed |
AMD8664 is orally available analogue of AMD3100 |
| TAK-779 |
Takeda
Pharmaceuticals |
Being studied in combination with T-20 |
| HE2000 |
Hollis-Eden Pharmaceuticals |
Phase I/II enrolling in U.S.; info from company, other
|
| PRO 140 |
Progenics Pharmaceuticals |
Moving into Phase I/II; press release
|
| PRO 367 |
Progenics Pharmaceuticals |
Phase I recently
completed |
| Hu5A8 |
Tanox
Biosystems, Inc. |
Phase I clinical study began 8/1/01 |
| PEHRG214 |
Virionyx |
Phase
I at Boston Deaconess
Hospital, 3/01 |
| HIV NCp7 |
Achillion Pharmaceuticals |
Pre-clinical; also in Phase I
for HBV |
| SPD-756 |
Shire Pharmaceuticals PLC |
Formerly BCH-13520 |
|
Fd4C/ACH-126,443 |
Achillion
Pharmaceuticals |
L. Dunkle on this,
but will it go the way of other ‘F’ drugs? |
| 5-helix |
Howard
Hughes Medical Inst. |
Science
2001, 291: 884-888 |
|
ADA (azidocarbonamide) |
Hubriphar |
Phase I/II: AIDS
2001, 15:33-45
|
| S1360 |
Shionogi Pharmaceuticals |
Animal safety data at 9CROI; Human study underway |
| TAK-449 |
Takeda
Pharmaceuticals |
Company
officials refused request for information |
| T-649 |
Trimeris/Roche
|
Similar to T-1249; paper at 7/01 IAS meeting
|
| BMS-806 |
Bristol-Myers Squibb |
In vitro results at 9CROI; Human trial to start later this year |
| Merck integrase inhibitor |
Merck |
Phase I studies to commence March 2002 |
| Merck prime-boost vaccine |
Merck |
Safety trials in HIV-negative volunteers currently underway |
| Missing in Action |
|
L-756,423/MK-944A |
Merck |
Reportedly moving into Phase
II/III; paper at 7CROI
|
|
AG-1776/JE-2147 |
Agouron
(Pfizer) |
All
appearances suggest this drug is history. |
| L-708,906, L-731,988 |
Merck |
Hazuda,
D.J., et al. Science 287(Jan. 28):646 (also, Science News) |
| Didox, Trimodox |
Molecules for Health |
Ribonucleotide reductase inhibitors -- circa 1995
|
| AOP-RANTES |
Gryphon Sciences |
Animal (mouse) data only, J Virol 5/99, paper as summer IAS
|
| FP-21399 |
Lexigen Pharmaceuticals |
Bruce
Dezube again: J Infect Dis 2000 182:607-10 |
| PRO2000 |
Genetics (formerly Procept) |
Being tested as topical microbicide
at Fenway Center |
| HGTV43 |
Enzo
Biochem, Inc. |
Paper at summer IAS
meeting
|
| SJ-3366 |
Samjin Pharmaceuticals Ltd. |
Paper at 14th Intl.
Conf. on Antiviral Research, 4/01 |
This article was provided by Treatment Action Group. It is a part of the publication TAGline.
Email
Print-Friendly
Glossary
